🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Outlook Therapeutics And 4 Other Penny Stocks Bought By Insiders

Published 24/02/2022, 12:53
© Reuters.  Outlook Therapeutics And 4 Other Penny Stocks Bought By Insiders
LPTH
-
IVDN
-

Asian markets tumbled on Thursday after news emerged that Russia’s President Vladimir Putin has announced a “special military operation” in Ukraine. Investors, meanwhile, focused on some notable insider trades

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Innovative Designs

  • The Trade: Innovative Designs, Inc. (OTC: IVDN) Director Dean Kolocouris acquired a total of 25,000 shares at an average price of $0.25. To acquire these shares, it cost $6.25 thousand.
  • What’s Happening: The company’s stock gained around 3% over the previous month.
  • What Innovative Designs Does: Innovative Designs Inc markets cold-weather recreational and industrial clothing products, as well as house wrap, which is made from INSULTEX, a low density foamed polyethylene with buoyancy, scent block and thermal resistant properties.
Emmaus Life Sciences
  • The Trade: Emmaus Life Sciences, Inc. (OTC: EMMA) CEO and Chairman Yutaka Niihara acquired a total of 19,300 shares at an average price of $1.44. The insider spent around $27.78 thousand to buy those shares.
  • What’s Happening: The company’s shares fell around 8% since the start of the year.
  • What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases.
Also check this: Executives Buy Over $70M Of 4 Stocks

Pacific Health Care Organization

  • The Trade: Pacific Health Care Organization, Inc. (OTC: PFHO) CEO and President Tom Kubota acquired a total of 18,000 shares at an average price of $0.81. To acquire these shares, it cost around $14.53 thousand.
  • What’s Happening: The company’s stock tumbled 26% over the previous six months.
  • What Pacific Health Care Organization Does: Pacific Health Care Organization Inc is a specialty workers' compensation managed care company. The company serves any size employer in the state of California as well as insurers, third-party administrators, self-administered employers, municipalities and other industries.
LightPath Technologies
  • The Trade: LightPath Technologies, Inc. (NASDAQ: LPTH) Chief Financial Officer Albert Miranda acquired a total of 5,000 shares at an average price of $2.00. The insider spent $10 thousand to buy those shares.
  • What’s Happening: Lightpath Technologies recently filed for mixed shelf of up to $75.8 million.
  • What LightPath Technologies Does: LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets.
Outlook Therapeutics
  • The Trade: Outlook Therapeutics, Inc. (NASDAQ: OTLK) Director Kurt Hilzinger acquired a total of 175,132 shares at an average price of $1.47. The insider spent $256.97 thousand to buy those shares.
  • What’s Happening: Outlook Therapeutics recently posted a Q1 loss of $0.08 per share.
  • What Outlook Therapeutics Does: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.